Epitope screening method capable of exciting anti-mycobacterium tuberculosis protective immunological reaction of body and uses

Abstract

The invention relates to a selection method for epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the function thereof, in particular to the molecule mimic peptide of the epitope with vaccine development prospect from the mycobacterium tuberculosis and the coding DNA thereof. The selection method of epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the function thereof provides T lymphocyte epitope contained in one important gene Ag85B in the research of mycobacterium tuberculosisand the method of deducting or selecting the epitope, which is beneficial to further developing novel multivalent and poly epitope tuberculosis vaccine and prevent and control the happening and development of tuberculosis; the method makes a foundation of the future development of synthesizing peptide vaccine epitope vaccine and dna vaccine by using epitope and provides molecule mimic peptide of epitope which can stimulate the protective immune response of the body anti-mycobacterium tuberculosis and the peptide has the amino acid sequence of FVRSSNLKFQDAYNA(SEQ ID NO:1).

Description

technical field [0001] The invention belongs to the field of molecular immunology, and specifically relates to an antigenic epitope screening method capable of stimulating a body's protective immune response against Mycobacterium tuberculosis (MTb) and its application. Background technique [0002] Tuberculosis is a chronic infectious disease. It is a necrotic disease caused by a bacterium called Mycobacterium tuberculosis (Mtb) invading the body. It may occur in any part or organ of the body, among which the lungs are the most vulnerable. At present, Mycobacterium tuberculosis is still an important pathogenic microorganism that seriously endangers human health. Every year, it will cause infection of more than 10 million people and cause death of about 3 million people worldwide. With the continuous emergence of drug-resistant strains of Mycobacterium tuberculosis in recent years and BCG as the only vaccine currently used to prevent tuberculosis, the immune protection effect...

AI Technical Summary

Problems solved by technology

With the continuous emergence of drug-resistant strains of Mycobacterium tuberculosis in recent years and BCG as the only vaccine currently used to prevent tuberculosis, the immune protection effect is unstable; after vaccination, the tuberculin test is positive, which interferes with the diagnosis of tuberculosis and delays the timing of treatment; Severe disseminated tuberculosis may occur after vaccination in immunocompromised patients such as AIDS

Images